CJC-1295 DAC

CJC-1295 DAC is a synthetic GHRH analog with a Drug Affinity Complex (DAC) that binds albumin in vivo, extending its half-life from minutes (native GHRH) to ~8 days. This creates a fundamentally different pharmacological profile from CJC-1295 without DAC (mod-GRF 1-29): instead of producing discrete GH pulses, CJC-1295 DAC creates sustained, tonic elevation of GH and IGF-1 — more like a continuous GH infusion than pulsatile release. The original Conjuchem Phase II data showed a single 60 mcg/kg injection elevated mean GH levels 2-10x above baseline for 6+ days and IGF-1 by 1.5-3x for 9-11 days. This is both its advantage (one injection per week) and its controversy: the loss of pulsatile GH release may reduce GH receptor sensitivity over time and cause more side effects (water retention, insulin resistance) than pulsatile protocols. Most peptide clinicians now prefer CJC-1295 no-DAC (mod-GRF 1-29) for this reason, but CJC-1295 DAC remains popular for its convenience. Never combine with other sustained GH elevation approaches (MK-677) due to additive insulin resistance risk.